Azithromycin in the prophylaxis of opportunistic infections in AIDS. NLM AIDSLINE Important note: Information in this article was accurate in 1996. The state of the art may have changed since the publication date.

Click here to return to AIDSLINE main menu
DonateNow
Print this Article


Azithromycin in the prophylaxis of opportunistic infections in AIDS.

Int J STD AIDS. 1996;7 Suppl 1:34-7. Unique Identifier : AIDSLINE MED/96230319
McCutchan JA; UCSD Treatment Center, Department of Medicine, San Diego,; California, USA.

Abstract: Prevention of opportunistic infections contributes to improved quality of life and survival in individuals with acquired immunodeficiency syndrome (AIDS). Agents which are more effective and convenient, less costly, and better tolerated are needed for multiple organism primary prophylaxis. Azithromycin, azalide with high and prolonged intracellular levels, promise to provide to protection against Mycobacterium avium complex (MAC) disease in those with advanced AIDS when given weekly. A large trail comparing rifabutin (300 mg daily), a currently approved primary prophylactic agent for MAC, with azithromycin (1200 mg weekly) has been completed and is under analysis. If weekly azithromycin provides equivalent or better protection from disseminated MAC, the cost effectiveness and convenience of MAC prophylaxis may be improved.
Keywords: Antibiotics, Antitubercular/THERAPEUTIC USE Antibiotics, Macrolide/*THERAPEUTIC USE Azithromycin/*THERAPEUTIC USE AIDS-Related Opportunistic Infections/*PREVENTION & CONTROL Clarithromycin/THERAPEUTIC USE Clinical Trials Human Mycobacterium avium-intracellulare Infection/*PREVENTION & CONTROL Rifabutin/THERAPEUTIC USE JOURNAL ARTICLEKWDantibiotics,antitubercular/therapeuticuseantibiotics,macrolide/KWDtherapeuticuseazithromycin/KWDtherapeuticuseaids-relatedopportunisticinfections/KWDprevention&controlclarithromycin/therapeuticuseclinicaltrialshumanmycobacteriumavium-intracellulareinfection/KWDprevention&controlrifabutin/therapeuticusejournalarticle
961030
M96A1419

Copyright © 1996 - National Library of Medicine. Reproduced under license with the National Library of Medicine, Bethesda, MD.

AEGiS is a 501(c)3, not-for-profit, tax-exempt, educational corporation. AEGiS is made possible through unrestricted funding from Boehringer Ingelheim, Bridgestone/Firestone Charitable Trust, Bristol-Myers Squibb Company, Elton John AIDS Foundation, Gill Foundation, the National Library of Medicine, Quest Diagnostics, Roche and Trimeris, and donations from users like you. Always watch for outdated information. This article first appeared in 1996. This material is designed to support, not replace, the relationship that exists between you and your doctor.

AEGiS presents published material, reprinted with permission and neither endorses nor opposes any material. All information contained on this website, including information relating to health conditions, products, and treatments, is for informational purposes only. It is often presented in summary or aggregate form. It is not meant to be a substitute for the advice provided by your own physician or other medical professionals. Always discuss treatment options with a doctor who specializes in treating HIV.

Copyright ©1980, 1996. AEGiS. All materials appearing on AEGiS are protected by copyright as a collective work or compilation under U.S. copyright and other laws and are the property of AEGiS, or the party credited as the provider of the content. .